369 related articles for article (PubMed ID: 28741064)
1. Injectable Sustained-Release Depots of PLGA Microspheres for Insoluble Drugs Prepared by hot-Melt Extrusion.
Guo Y; Yang Y; He L; Sun R; Pu C; Xie B; He H; Zhang Y; Yin T; Wang Y; Tang X
Pharm Res; 2017 Oct; 34(10):2211-2222. PubMed ID: 28741064
[TBL] [Abstract][Full Text] [Related]
2. In Vitro-In Vivo Relationship of Amorphous Insoluble API (Progesterone) in PLGA Microspheres.
Pu C; Wang Q; Zhang H; Gou J; Guo Y; Tan X; Xie B; Yin N; He H; Zhang Y; Wang Y; Yin T; Tang X
Pharm Res; 2017 Dec; 34(12):2787-2797. PubMed ID: 28948463
[TBL] [Abstract][Full Text] [Related]
3. Microsphere delivery of Risperidone as an alternative to combination therapy.
D'Souza S; Faraj J; DeLuca P
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):631-9. PubMed ID: 23892159
[TBL] [Abstract][Full Text] [Related]
4. Effect of mPEG-PLGA on Drug Crystallinity and Release of Long-Acting Injection Microspheres: In Vitro and In Vivo Perspectives.
Xing D; Tang L; Yang H; Yan M; Yuan P; Wu Y; Zhang Y; Yin T; Wang Y; Gou J; Tang X; He H
Pharm Res; 2024 Jun; 41(6):1271-1284. PubMed ID: 38839720
[TBL] [Abstract][Full Text] [Related]
5. Development of andrographolide loaded PLGA microspheres: optimization, characterization and in vitro-in vivo correlation.
Jiang Y; Wang F; Xu H; Liu H; Meng Q; Liu W
Int J Pharm; 2014 Nov; 475(1-2):475-84. PubMed ID: 25219858
[TBL] [Abstract][Full Text] [Related]
6. Influence of formulation composition and process on the characteristics and in vitro release from PLGA-based sustained release injectables.
Meeus J; Scurr DJ; Appeltans B; Amssoms K; Annaert P; Davies MC; Roberts CJ; Van den Mooter G
Eur J Pharm Biopharm; 2015 Feb; 90():22-9. PubMed ID: 25448071
[TBL] [Abstract][Full Text] [Related]
7. Core/shell PLGA microspheres with controllable in vivo release profile via rational core phase design.
Yu M; Yao Q; Zhang Y; Chen H; He H; Zhang Y; Yin T; Tang X; Xu H
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):1070-1079. PubMed ID: 29484961
[TBL] [Abstract][Full Text] [Related]
8. Preparation and physicochemical characterization of T-OA PLGA microspheres.
Fu J; Dong XX; Zeng ZP; Yin XB; Li FW; Ni J
Chin J Nat Med; 2017 Dec; 15(12):912-916. PubMed ID: 29329648
[TBL] [Abstract][Full Text] [Related]
9. Tracking the effect of microspheres size on the drug release from a microsphere/sucrose acetate isobutyrate (SAIB) hybrid depot in vitro and in vivo.
Lin X; Wang J; Xu Y; Tang X; Chen J; Zhang Y; Zhang Y; Yang Z
Drug Dev Ind Pharm; 2016 Sep; 42(9):1455-65. PubMed ID: 26790718
[TBL] [Abstract][Full Text] [Related]
10. Validation of a cage implant system for assessing in vivo performance of long-acting release microspheres.
Doty AC; Hirota K; Olsen KF; Sakamoto N; Ackermann R; Feng MR; Wang Y; Choi S; Qu W; Schwendeman A; Schwendeman SP
Biomaterials; 2016 Dec; 109():88-96. PubMed ID: 27693924
[TBL] [Abstract][Full Text] [Related]
11. Zero order controlled release delivery of cholecalciferol from injectable biodegradable microsphere: In-vitro characterization and in-vivo pharmacokinetic studies.
Vora L; V G S; Vavia P
Eur J Pharm Sci; 2017 Sep; 107():78-86. PubMed ID: 28629804
[TBL] [Abstract][Full Text] [Related]
12. Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres.
Mao S; Xu J; Cai C; Germershaus O; Schaper A; Kissel T
Int J Pharm; 2007 Apr; 334(1-2):137-48. PubMed ID: 17196348
[TBL] [Abstract][Full Text] [Related]
13. Prediction of dexamethasone release from PLGA microspheres prepared with polymer blends using a design of experiment approach.
Gu B; Burgess DJ
Int J Pharm; 2015 Nov; 495(1):393-403. PubMed ID: 26325309
[TBL] [Abstract][Full Text] [Related]
14. Sustained release of risperidone from biodegradable microspheres prepared by in-situ suspension-evaporation process.
An T; Choi J; Kim A; Lee JH; Nam Y; Park J; Sun Bk; Suh H; Kim CJ; Hwang SJ
Int J Pharm; 2016 Apr; 503(1-2):8-15. PubMed ID: 26899975
[TBL] [Abstract][Full Text] [Related]
15. Design of Controlled Release PLGA Microspheres for Hydrophobic Fenretinide.
Zhang Y; Wischke C; Mittal S; Mitra A; Schwendeman SP
Mol Pharm; 2016 Aug; 13(8):2622-30. PubMed ID: 27144450
[TBL] [Abstract][Full Text] [Related]
16. Sophoridine-loaded PLGA microspheres for lung targeting: preparation, in vitro, and in vivo evaluation.
Wang W; Cai Y; Zhang G; Liu Y; Sui H; Park K; Wang H
Drug Deliv; 2016 Nov; 23(9):3674-3680. PubMed ID: 27689622
[TBL] [Abstract][Full Text] [Related]
17. Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation.
Su ZX; Shi YN; Teng LS; Li X; Wang LX; Meng QF; Teng LR; Li YX
Pharm Dev Technol; 2011 Aug; 16(4):377-84. PubMed ID: 20370594
[TBL] [Abstract][Full Text] [Related]
18. The angiogenic effect of ONO-1301, a novel long-acting prostacyclin agonist loaded in PLGA microspheres prepared using different molecular weights of PLGA, in a murine sponge model.
Hazekawa M; Morihata K; Yoshida M; Sakai Y; Uchida T
Drug Dev Ind Pharm; 2014 Nov; 40(11):1435-42. PubMed ID: 23937583
[TBL] [Abstract][Full Text] [Related]
19. Development of Recombinant Human Growth Hormone (rhGH) sustained-release microspheres by a low temperature aqueous phase/aqueous phase emulsion method.
Kang J; Wu F; Cai Y; Xu M; He M; Yuan W
Eur J Pharm Sci; 2014 Oct; 62():141-7. PubMed ID: 24907681
[TBL] [Abstract][Full Text] [Related]
20. Preparation of ONO-1301-loaded poly(lactide-co-glycolide) microspheres and their effect on nerve conduction velocity.
Hazekawa M; Sakai Y; Yoshida M; Haraguchi T; Morisaki T; Uchida T
J Pharm Pharmacol; 2011 Mar; 63(3):362-8. PubMed ID: 21749383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
